ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Milano, Lombardia, ITA:

Locations recently updated

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Milano, MI, Italy and 66 other locations

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Milano, Italy and 34 other locations

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Milano, Italy and 89 other locations

Locations recently updated

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Milano, Italy and 75 other locations

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Milano, Lombardia, Italy and 186 other locations

IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

Phase 1

Iksuda Therapeutics

Milano, Italy and 12 other locations

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Milano, Italy and 31 other locations

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Bergamo, Italy and 56 other locations

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in...

Active, not recruiting
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Drug: VAY736
Drug: lenalidomide

Phase 1

Novartis
Novartis

Rozzano, MI, Italy and 9 other locations

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...

Enrolling
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Dexamethasone
Drug: Ifosfamide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Novara, Piedmont, Italy and 57 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems